Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $18.00 by Analysts at Truist Financial

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target cut by Truist Financial from $21.00 to $18.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

YMAB has been the subject of a number of other reports. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Morgan Stanley reduced their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday. Finally, Bank of America reduced their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.30.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $4.85 on Wednesday. The firm has a 50-day moving average of $6.46 and a 200-day moving average of $10.62. The company has a market cap of $217.23 million, a PE ratio of -8.98 and a beta of 0.65. Y-mAbs Therapeutics has a one year low of $4.25 and a one year high of $18.19.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the firm earned ($0.02) earnings per share. On average, equities research analysts expect that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in YMAB. Principal Financial Group Inc. purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at approximately $267,000. Intech Investment Management LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at approximately $133,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Y-mAbs Therapeutics by 9.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock valued at $3,676,000 after buying an additional 23,982 shares in the last quarter. FMR LLC lifted its stake in shares of Y-mAbs Therapeutics by 23.1% during the 3rd quarter. FMR LLC now owns 36,416 shares of the company’s stock valued at $479,000 after buying an additional 6,822 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at approximately $44,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.